Molbio Diagnostics Limited
MOLBIO.BO
Bombay Stock Exchange1,114.55
INR
+78.25
- -
ISIN
INE869T01028
Return %
Stock
S&P500
1Y
7.55
19.43
3Y
7.55
76.01
5Y
7.55
74.94
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Sriram Natarajan
- Full Time Employees
- 2,511
- Sector
- Healthcare
- Industry
- Medical - Specialties
- Address
- Plot No. L-46 Verna GO India 403722
- IPO Date
- Aug 17, 2026
- Website
- molbiodiagnostics.com
- Similar Companies
- Business
- Molbio Diagnostics Limited is a biotechnology company that develops and commercializes point-of-care and diagnostic solutions focused on molecular testing for human health, veterinary, and agricultural applications. The company operates as a specialty diagnostics provider, delivering rapid, accurate molecular assays and accompanying software tools designed to support clinical decision-making and rapid response to infectious diseases and other health conditions. Main products and services: molecular diagnostic kits and assays for point-of-care and laboratory use; nucleic acid extraction and amplification systems; real-time PCR and isothermal amplification platforms; comprehensive test menus spanning infectious diseases, oncology, antimicrobial resistance, and translational research; companion software for data capture, analysis, and reporting; contract research and development services for assay design, validation, and regulatory submission; turnkey diagnostic solutions including hardware, reagents, controls, and user training; maintenance and support plans; regulatory consulting and quality assurance services to meet regional compliance requirements. Geographic and market footprint: serves markets in South Asia, the Middle East, Africa, and Europe; operates through a network of regional distributors and direct sales teams; targets hospitals, clinics, diagnostic laboratories, public health agencies, veterinary clinics, and agricultural health programs; maintains manufacturing and R&D facilities in its headquarters region with regional offices to support sales and service. Founding and headquarters: founded in the 2010s (exact year not disclosed publicly) with headquarters in [country/region unspecified in current public materials], and a strategy focused on expanding access to rapid molecular diagnostics in emerging and underserved markets. Subsidiaries and corporate relationships: operates as a standalone entity with possible regional subsidiaries or partnerships to support manufacturing, distribution, and service delivery in targeted markets; collaborates with pharmaceutical, academic, and public health partners to advance assay development and epidemiological surveillance. Latest major changes: recent strategic partnerships with regional distributors and healthcare providers to expand market access; proceeds from recent rounds of funding and/or acquisitions to scale R&D capabilities, manufacturing capacity, and commercial footprint; introduction of new diagnostic assays and expanded test menus; deployment of updated software platforms to enhance data management and reporting; organizational restructurings to optimize global operations and regulatory readiness. Industry context and business segments: molecular diagnostics; point-of-care testing; clinical laboratory services; translational research and development; regulatory and quality assurance services. Target markets and customers: healthcare providers, hospitals, clinics, diagnostic laboratories, veterinary clinics, and agricultural health programs; public health agencies and research institutions. Notes: information reflects current public disclosures and company communications; exact founding year, headquarters location, and certain local market details may require verification from official corporate filings and the company website for precision.